The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria.
Publication/Presentation Date
11-1-2021
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a lethal aggressive cancer, in part due to elements of the microenvironment (hypoxia, hypoglycemia) that cause metabolic network alterations. The FDA-approved antihelminthic pyrvinium pamoate (PP) has previously been shown to cause PDAC cell death, although the mechanism has not been fully determined. We demonstrated that PP effectively inhibited PDAC cell viability with nanomolar IC50 values (9-93 nmol/L) against a panel of PDAC, patient-derived, and murine organoid cell lines.
Volume
20
Issue
11
First Page
2166
Last Page
2176
ISSN
1538-8514
Published In/Presented At
Schultz, C. W., McCarthy, G. A., Nerwal, T., Nevler, A., DuHadaway, J. B., McCoy, M. D., Jiang, W., Brown, S. Z., Goetz, A., Jain, A., Calvert, V. S., Vishwakarma, V., Wang, D., Preet, R., Cassel, J., Summer, R., Shaghaghi, H., Pommier, Y., Baechler, S. A., Pishvaian, M. J., … Brody, J. R. (2021). The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria. Molecular cancer therapeutics, 20(11), 2166–2176. https://doi.org/10.1158/1535-7163.MCT-20-0652
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
34413127
Department(s)
Administration and Leadership
Document Type
Article